Study finds immune cells undermine cancer therapy by triggering their own death

A team of Memorial Sloan Kettering Cancer Center (MSK) researchers have made an important finding about why genetically engineered immune cells sometimes fail to finish the job when given as a cancer treatment. The new discovery sheds light on the tendency of these modified cells to lose power or even self-destruct before fully destroying a tumor. This is a major problem, for example, in chimeric antigen receptor (CAR) T cell therapy.

👉 Full Story